Michael L Maitland

List of Publications by Year
in descending order

36	2,027	430874	395702
papers	citations	18 h-index	33 g-index

37	37	37	3158
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. Pharmacogenetics and Genomics, 2022, Publish Ahead of Print, .	1.5	1
2	Evaluation of publicly available in vitro drug sensitivity models for ovarian and uterine cancer. Gynecologic Oncology, 2021, 160, 295-301.	1.4	0
3	Identifying Novel Drug Targets by iDTPnd: A Case Study of Kinase Inhibitors. Genomics, Proteomics and Bioinformatics, 2021, 19, 986-997.	6.9	1
4	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibodyâ€“Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 4511-4520.	7.0	39
5	Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation. Clinical Cancer Research, 2020, 26, 6464-6474.	7.0	16
6	Get Real: Integration of Realâ€World Data to Improve Patient Care. Clinical Pharmacology and Therapeutics, 2020, 107, 722-725.	4.7	6
7	Cancer Clinical Investigators Should Converge with Pharmacometricians. Clinical Cancer Research, 2019, 25, 5182-5184.	7.0	3
8	Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. British Journal of Cancer, 2018, 118, 1042-1050.	6.4	27
9	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	2.1	14
10	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 82, 309-317.	2.3	12
11	Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2574-2574.	1.6	2
12	PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.. Journal of Clinical Oncology, 2018, 36, 5565-5565.	1.6	18
13	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 298-306.	2.6	26
14	Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemotherapy and Pharmacology, 2017, 80, 29-36.	2.3	24
15	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. Cancer Research, 2016, 76, 117-126.	0.9	36
16	Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clinical Cancer Research, 2015, 21, 5092-5099.	7.0	3
17	Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. Journal of the National Cancer Institute, 2015, 107, djv247.	6.3	18
18	Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib. Clinical Cancer Research, 2015, 21, 365-372.	7.0	29

#	Article	IF	Citations
19	Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer, 2014, 14, 5.	2.6	3
20	More Sound Cancer Therapy Biomarker Development With Active Noise Control. Oncologist, 2013, 18, 239-241.	3.7	2
21	Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients. Clinical Cancer Research, 2013, 19, 3059-3067.	7.0	33
22	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolboxâ€"Point. Cancer Research, 2012, 72, 5145-5149.	0.9	77
23	Clinical trials in the era of personalized oncology. Ca-A Cancer Journal for Clinicians, 2011, 61, 365-381.	329.8	56
24	Advances in biomarkers for targeted agents. Clinical Advances in Hematology and Oncology, 2011, 9, 688-90.	0.3	0
25	Vascular endothelial growth factor pathway. Pharmacogenetics and Genomics, 2010, 20, 346-349.	1.5	18
26	Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. Journal of Biomedical Informatics, 2010, 43, 376-384.	4.3	32
27	Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology. Clinical Cancer Research, 2010, 16, 5296-5302.	7.0	46
28	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. Journal of the National Cancer Institute, 2010, 102, 596-604.	6.3	381
29	Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment. Clinical Cancer Research, 2009, 15, 6250-6257.	7.0	156
30	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	2.8	605
31	Cardiovascular toxicity of new agents. Clinical Advances in Hematology and Oncology, 2008, 6, 657-9.	0.3	2
32	Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 1455-1461.	6.3	156
33	Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer, 2006, 54, 243-245.	2.0	15
34	TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?. Trends in Pharmacological Sciences, 2006, 27, 432-437.	8.7	87
35	Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets. Annals of Internal Medicine, 2006, 145, 702.	3.9	39
36	Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics. Journal of Clinical Oncology, 2006, 24, 2151-2157.	1.6	44